Peptide News Digest

#Public-Comment

3 stories

Regulatory · View digest

American Pharmacists Association (APhA) Formally Submits Docket Comments to FDA-2025-N-6895 Urging the Pharmacy Compounding Advisory Committee to Prioritize Patient Safety, Scientific Evidence, and Regulatory Oversight in the July 23-24 Review of Seven Peptide Substances; Statement From APhA Vice President of Professional Affairs Brigid Groves, PharmD, MS: 'Pharmacists Believe in Innovation, But Innovation Must Be Grounded in Science and Patient Safety' — The Filing Joins Partnership for Safe Medicines, Public Citizen, and Institute for Safe Medication Practices in the Formal Public-Comment Record

The American Pharmacists Association (APhA) submitted comments to FDA docket FDA-2025-N-6895 on Thursday July 17, 2026 urging the Pharmacy Compounding Advisory Committee to prioritize patient safety, scientific evidence, and regulatory oversight when evaluating the seven peptide substances up for review July 23-24. APhA warned that current black and gray markets for peptides expose patients to significant risks including contamination, inaccurate dosing, counterfeit ingredients, and serious adverse health consequences. Brigid Groves, PharmD, MS, APhA Vice President of Professional Affairs, said in the associated statement: 'Pharmacists believe in innovation, but innovation must be grounded in science and patient safety.' APhA emphasized that compounding pharmacists have a long history of helping patients access customized and safely prepared therapies when there is a legitimate clinical need, and that if rigorous peer-reviewed research demonstrates safety and efficacy for the seven peptides under review, pharmacists will play an essential role in preparing high-quality compounded formulations. The APhA filing joins docket comments from the Partnership for Safe Medicines (opposing addition), Public Citizen (opposing addition), Institute for Safe Medication Practices (raising safety concerns), the Alliance for Pharmacy Compounding (supporting bulks-list inclusion with quality safeguards), and individual academic scientists including UC Davis's Paul Knoepfler.

Regulatory · View digest

PCAC July 23-24 Public Comment Window Set: Written Submissions Close July 9, Oral Presentation Requests Close June 30

The Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 — at which seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) will be discussed for 503A compounding inclusion — now has firm public-comment deadlines. Written submissions are due July 9, 2026 via regulations.gov; oral presentation requests close June 30, with the FDA allocating presentation slots after review. The PCAC review follows the April 23, 2026 effective date when 12 peptides came off the FDA's Category 2 bulks list. Industry stakeholders, patient groups, and clinicians are organizing through the SSRPi network and the Alliance for Pharmacy Compounding to coordinate testimony. The combined regulatory cycle — PCAC plus the parallel April 30 503B bulks-list proposal closing June 29 — will reshape the compounding-pharmacy economy through 2027 and determine which research peptides remain accessible through licensed channels.

Regulatory · View digest

FDA Pharmacy Compounding Advisory Committee Public Docket FDA-2025-N-6895 Open for Comments Ahead of July 23–24 Peptide Review

The FDA's PCAC public docket FDA-2025-N-6895 is now accepting written comments on the proposed addition of seven peptides to the Section 503A bulk drug substances list ahead of the July 23–24 advisory committee meeting at White Oak. Day 1 will cover BPC-157, KPV, TB-500, and MOTs-C; Day 2 will cover Emideltide (DSIP), Semax, and Epitalon. Comments received by July 9 are guaranteed to be presented to the committee, and the docket closes July 22. The window gives compounders, prescribers, and patient advocates roughly twelve weeks to formally submit clinical evidence, pharmacovigilance data, and access arguments.